vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). Astera Labs, Inc. runs the higher net margin — 16.6% vs 11.1%, a 5.5% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs 29.6%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $29.1M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 34.1%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ALAB vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $247.1M |
| Net Profit | $45.0M | $27.5M |
| Gross Margin | 75.6% | — |
| Operating Margin | 24.7% | 14.1% |
| Net Margin | 16.6% | 11.1% |
| Revenue YoY | 91.8% | 29.6% |
| Net Profit YoY | 82.0% | 367.5% |
| EPS (diluted) | $0.25 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $247.1M | ||
| Q3 25 | $230.6M | $227.8M | ||
| Q2 25 | $191.9M | $211.4M | ||
| Q1 25 | $159.4M | $197.1M | ||
| Q4 24 | $141.1M | $190.6M | ||
| Q3 24 | $113.1M | $148.3M | ||
| Q2 24 | $76.8M | $138.0M | ||
| Q1 24 | $65.3M | $137.4M |
| Q4 25 | $45.0M | $27.5M | ||
| Q3 25 | $91.1M | $26.6M | ||
| Q2 25 | $51.2M | $8.5M | ||
| Q1 25 | $31.8M | $15.7M | ||
| Q4 24 | $24.7M | $-10.3M | ||
| Q3 24 | $-7.6M | $-24.2M | ||
| Q2 24 | $-7.5M | $-2.3M | ||
| Q1 24 | $-93.0M | $18.2M |
| Q4 25 | 75.6% | — | ||
| Q3 25 | 76.2% | — | ||
| Q2 25 | 75.8% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.0% | — | ||
| Q3 24 | 77.7% | — | ||
| Q2 24 | 77.9% | — | ||
| Q1 24 | 77.4% | — |
| Q4 25 | 24.7% | 14.1% | ||
| Q3 25 | 24.0% | 15.9% | ||
| Q2 25 | 20.7% | 6.6% | ||
| Q1 25 | 7.1% | 13.3% | ||
| Q4 24 | 0.1% | -2.3% | ||
| Q3 24 | -7.9% | -13.8% | ||
| Q2 24 | -31.7% | 3.7% | ||
| Q1 24 | -127.1% | 14.8% |
| Q4 25 | 16.6% | 11.1% | ||
| Q3 25 | 39.5% | 11.7% | ||
| Q2 25 | 26.7% | 4.0% | ||
| Q1 25 | 20.0% | 8.0% | ||
| Q4 24 | 17.5% | -5.4% | ||
| Q3 24 | -6.7% | -16.3% | ||
| Q2 24 | -9.8% | -1.7% | ||
| Q1 24 | -142.5% | 13.2% |
| Q4 25 | $0.25 | $1.14 | ||
| Q3 25 | $0.50 | $1.13 | ||
| Q2 25 | $0.29 | $0.36 | ||
| Q1 25 | $0.18 | $0.69 | ||
| Q4 24 | $1.23 | $-0.45 | ||
| Q3 24 | $-0.05 | $-1.27 | ||
| Q2 24 | $-0.05 | $-0.14 | ||
| Q1 24 | $-1.77 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $285.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $540.7M |
| Total Assets | $1.5B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $285.6M | ||
| Q3 25 | $140.4M | $262.6M | ||
| Q2 25 | $162.3M | $217.8M | ||
| Q1 25 | $86.4M | $149.8M | ||
| Q4 24 | $79.6M | $144.9M | ||
| Q3 24 | $126.1M | $145.0M | ||
| Q2 24 | $421.1M | $240.1M | ||
| Q1 24 | $696.1M | $228.6M |
| Q4 25 | $1.4B | $540.7M | ||
| Q3 25 | $1.3B | $505.8M | ||
| Q2 25 | $1.1B | $436.8M | ||
| Q1 25 | $1.0B | $418.6M | ||
| Q4 24 | $964.8M | $403.7M | ||
| Q3 24 | $889.6M | $405.9M | ||
| Q2 24 | $845.3M | $455.8M | ||
| Q1 24 | $808.8M | $452.0M |
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $983.1M | $1.3B | ||
| Q2 24 | $915.5M | $920.8M | ||
| Q1 24 | $864.9M | $914.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $30.4M |
| Free Cash FlowOCF − Capex | $76.6M | $29.1M |
| FCF MarginFCF / Revenue | 28.3% | 11.8% |
| Capex IntensityCapex / Revenue | 6.9% | 0.5% |
| Cash ConversionOCF / Net Profit | 2.12× | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $30.4M | ||
| Q3 25 | $78.2M | $44.1M | ||
| Q2 25 | $135.4M | $75.8M | ||
| Q1 25 | $10.5M | $35.0M | ||
| Q4 24 | $39.7M | $15.9M | ||
| Q3 24 | $63.5M | $12.5M | ||
| Q2 24 | $29.8M | $17.4M | ||
| Q1 24 | $3.7M | $18.3M |
| Q4 25 | $76.6M | $29.1M | ||
| Q3 25 | $65.9M | $38.0M | ||
| Q2 25 | $133.3M | $71.8M | ||
| Q1 25 | $6.0M | $32.5M | ||
| Q4 24 | $24.3M | $13.5M | ||
| Q3 24 | $46.8M | $7.7M | ||
| Q2 24 | $28.5M | $13.0M | ||
| Q1 24 | $228.0K | $13.7M |
| Q4 25 | 28.3% | 11.8% | ||
| Q3 25 | 28.6% | 16.7% | ||
| Q2 25 | 69.5% | 34.0% | ||
| Q1 25 | 3.7% | 16.5% | ||
| Q4 24 | 17.2% | 7.1% | ||
| Q3 24 | 41.4% | 5.2% | ||
| Q2 24 | 37.1% | 9.4% | ||
| Q1 24 | 0.3% | 10.0% |
| Q4 25 | 6.9% | 0.5% | ||
| Q3 25 | 5.3% | 2.7% | ||
| Q2 25 | 1.1% | 1.9% | ||
| Q1 25 | 2.8% | 1.3% | ||
| Q4 24 | 10.9% | 1.3% | ||
| Q3 24 | 14.8% | 3.2% | ||
| Q2 24 | 1.7% | 3.2% | ||
| Q1 24 | 5.2% | 3.3% |
| Q4 25 | 2.12× | 1.10× | ||
| Q3 25 | 0.86× | 1.66× | ||
| Q2 25 | 2.64× | 8.87× | ||
| Q1 25 | 0.33× | 2.23× | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
